Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
iCell Gene Therapeutics
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05212584CT.gov CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Refractory Hematologic Cancer
+42 more in the Refractory Hematologic Cancer cohort
Other indications for cd19-ucart
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BB · 71 |
| B-Cell Acute Lymphoblastic Leukemia | — | P2 | BB · 64 |
| Acute Lymphoblastic Leukemia | — | P2 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- RivoceranibZhengzhou UniversityBB
- Gm-CsfThe First Affiliated Hospital of Xiamen UniversityCCC
- Humanized, Dual-Affinity Re-Targeting, Or (Dart), Molecule That Recognizes Both Cd123 And Cd3City of Hope Medical CenterCCC
- Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)The First Affiliated Hospital of Xiamen UniversityCCC
- LenalidomideThe First Affiliated Hospital of Xiamen UniversityCCC
Citation
Floatz Terminal. cd19-ucart in Refractory Hematologic Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd19-ucart-refractory-hematologic-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →